Physician profile
Fredrick Wolk
NPI 1669426078
$6,037.75
in general payments reported to CMS, 2019-2025
28 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,791 · 2020: $174 · 2021: $958 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogpo LLC | $1,856.25 | 2019 | |
| Merck Sharp & Dohme LLC | $857.56 | 2019 | |
| Janssen Scientific Affairs, LLC | $757.50 | 2021 | |
| Astellas Pharma US INC | $420.00 | 2019-2025 | Padcev |
| Janssen Biotech, INC. | $397.04 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $310.89 | 2019-2020 | |
| Pfizer INC. | $244.35 | 2019 | |
| Abbvie INC. | $182.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.04 | 2019-2021 | |
| Genentech USA, INC. | $149.99 | 2019 | |
| Myovant Sciences Gmbh | $125.00 | 2021 | |
| Ferring Pharmaceuticals INC. | $124.75 | 2019 | |
| Amgen INC. | $105.63 | 2019 | |
| Blue Earth Diagnostics | $86.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $78.65 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $41.00 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $23.21 | 2019 | |
| Sagent Pharmaceuticals | $21.71 | 2019 | |
| Boston Scientific Corporation | $19.10 | 2019 | |
| Coloplast Corp | $17.66 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $17.35 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.58 | 2020 | |
| Allergan, INC. | $14.14 | 2019 | |
| Metuchen Pharmaceuticals | $13.75 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$428,655.55 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredrick Wolk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.